Pembrolizumab stories

Sep 21, 2026

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 20262 sources

Top claims

▪In the HARMONi-2 trial, patients with high PD-L1 expression of 50% or greater achieved a median overall survival that was not reached with ivonescimab compared to 23.2 months with pembrolizumab
▪Dr. Mariana Brandão cautioned that the control arm of pembrolizumab monotherapy in the phase 3 HARMONi-2 trial of ivonescimab versus pembrolizumab in PD-L1-positive advanced non-small cell lung cancer does not reflect global clinical practice, where anti-PD-1 therapy is typically combined with chemotherapy
▪In the phase 3 HARMONi-2 trial comparing ivonescimab with pembrolizumab in PD-L1-positive advanced non-small cell lung cancer, in the subgroup with PD-L1 expression of 1% to 49%, median overall survival was 28.5 months with ivonescimab compared to 22.1 months with pembrolizumab

Topics

Immunotherapy Drug Approval and Clinical Trials Clinical trials Cancer treatment breakthroughs

Related entities

Non-small cell lung cancer Lung cancer